Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

548.05
+7.791.44%
Post-market: 548.050.00000.00%19:52 EDT
Volume:1.07M
Turnover:589.66M
Market Cap:139.05B
PE:31.90
High:555.32
Open:545.10
Low:540.70
Close:540.26
52wk High:555.32
52wk Low:374.17
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.86
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.87
PE(LYR):35.77

Loading ...

Crinetics Pharmaceuticals: Financing Supported by $4.5 Bln of Fully Committed Bridge Financing from Bank of America, Morgan Stanley Senior Funding

THOMSON REUTERS
·
Jul 07

Crinetics Pharmaceuticals: Deal Expected to be Accretive Vertex's to Non-gaap Operating Income in 2029

THOMSON REUTERS
·
Jul 07

Crinetics Pharmaceuticals Inc: Vertex Will Acquire Crinetics for $85.00 Per Share in Cash

THOMSON REUTERS
·
Jul 07

Vertex Signs LOI with Pcpa for Alyftrek in Cystic Fibrosis Treatment

Reuters
·
Jul 06

Vertex Signs Letter of Intent for Cystic Fibrosis Therapy in Canada

MT Newswires Live
·
Jul 06

Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK

TIPRANKS
·
Jul 06

Vertex Pharmaceuticals - to Initiate Discussions for Public Listing of Alyftrek in Canada

THOMSON REUTERS
·
Jul 06

Vertex Signs Letter of Intent (loi) with the Pan-canadian Pharmaceutical Alliance for Alyftrek for the Treatment of Cystic Fibrosis

THOMSON REUTERS
·
Jul 06

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 03

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-07-02

Reuters
·
Jul 02

Movement Alert|Vertex Pharmaceuticals Rises 3.25% in Regular Trading, FDA Approves Casgevy Age Expansion to Children Aged Two and Older

Market Focus
·
Jul 02

Vertex Pharmaceuticals Says FDA Approves Expanded Use of Casgevy in Younger Children With Blood Disorders

MT Newswires Live
·
Jul 02

Vertex announces FDA approval for expanded use of Casgevy

TIPRANKS
·
Jul 02

Vertex Says FDA Expands Casgevy Approval to Sickle Cell, Beta Thalassemia Patients Age 2+

Reuters
·
Jul 02

Vertex Announces US FDA Approval for Expanded Use of Casgevy® for the Treatment of People Ages 2 Years and Older with Sickle Cell Disease or Transfusion-dependent Beta Thalassemia

THOMSON REUTERS
·
Jul 02

US FDA Approves Vertex's Gene Therapy for Sickle Cell Disease in Children as Young as Two

Reuters
·
Jul 02

Grants Casgevy Approval to Vertex Pharmaceuticals

THOMSON REUTERS
·
Jul 02

Vertex Minerals to Issue 12 Million Long-Dated Options on ASX

TIPRANKS
·
Jul 01

Vertex EVP, CMO Carmen Bozic Sells 596 Vertex Shares Worth $287,170‬

Reuters
·
Jul 01

Vertex Minerals Expands Share Capital Through Option Exercises

TIPRANKS
·
Jun 30